Table 1.
Characteristics of included trials
| Trial reference(s) | Intervention (n) | Control (n) | Major resections, n (%) | Cirrhosis, n (%) | Steatosis, n (%) | Vascular occlusion method |
Mean ischaemic time, min |
|
|---|---|---|---|---|---|---|---|---|
| Intervention | Control | |||||||
| Vriens et al. 200276 | Allopurinol (8) | Control (8) | Not stated | 0 | Not stated | Not stated | 53a | 45a |
| Tang et al. 2002, 200774,75 | Dextrose (29) | Control (28) | 38 (66.7) | 50 (87.7) | Not stated | Intermittent PTC | 19a | 21a |
| Holtje et al. 199960Marx et al. 200064 | Dopexamine (9) | Dopamine (10) | 19 (100) | Not stated | Not stated | Continuous PTC | 26a | 27a |
| Kostopanagiotou et al. 200662 | Mannitol (15) | Placebo (15) | 28 (93.3) | Not stated | Not stated | Continuous PTC | 33a | 34a |
| Aldrighetti et al. 2006,54 Finnazi et al. 2005,59 Pulitano et al. 2005, 200767–69 | Methylprednisolone (36) | Control (37) | 53 (72.6) | 26 (34.2) | 8 (10.9) | Intermittent PTC | 52a | 43a |
| Muratore et al. 200365 | Methylprednisolone (25) | Control (28) | 28 (52.8) | 16 (30.2) | 14 (26.4) | Continuous PTC | 41a | 37a |
| Yamashita et al. 200177 | Methylprednisolone (17) | Control (16) | 11 (33.3) | Not stated | Not stated | Continuous PTC or HHVO | Not stated | Not stated |
| Cerwenka et al. 199858 | Multivitamin (32) | Control (26) | 19 (32.8) | 13 (26) | Not stated | Continuous PTC | 48a | 48a |
| Cerwenka et al. 199957 | Multivitamin (25) | Control (25) | 19 (32.8) | Not stated | Not stated | Continuous PTC | 54a | 52a |
| Shirabe et al. 199671 | OKY 046 (9) | Control (8) | 9 (52.9) | Not stated | Not stated | Continuous HHVO | 35a | 40a |
| Kawano et al. 200561 | Prostaglandin E1 (10) | Control (12) | Not stated | Not stated | Not stated | Segmental PTC | 74a | 50a |
| Orii et al. 200066 | Prostaglandin E1 (15) | Amrinone (15), Control (15) | 0 | 45 (100) | Not stated | Intermittent PTC | 69a | 70a |
| Stadheim et al. 200072 | Prostaglandin E1 (13) | Pentoxifylline (10), Control (7) | 30 (100) | Not stated | Not stated | Afferent and efferent vessels | Not stateda | Not stateda |
| Sugawara et al. 199873 | Prostaglandin E1 (12) | Placebo (12) | Not stated | 24 (100) | Not stated | Continuous PTC | 70a | 73a |
| Beck-Schimmer et al. 200856 | Sevoflurane (30) | Propofol (34) | 28 (43.8) | 0 | 30 (46.9) | Continuous PTC | 36a | 35a |
| Settaf et al. 200170 | Trimetazidine (38) | Placebo (38) | Not stated | Not stated | Not stated | Continuous PTC | 40a | 40a |
| Li & Liang 200463 | Ulinastatin (16) | Gantaile (15) | Not stated | 27 (87.1) | Not stated | Continuous PTC | 18a | 17a |
| Bartels et al. 200455 | Vitamin E (19) | Placebo (28) | 33 (70.2) | Not stated | Not stated | Continuous PTC | 29a | 33a |
a
No significant difference between intervention and control group mean ischaemic times (P > 0.05)
PTC, portal triad clamping; HHVO, hemihepatic vascular occlusion